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Strengths and limitations of this study
 ► A wide range of stakeholders provided their reflec-
tions of the achievement of the ultimate goal of the 
national medicines information strategy 3 years af-
ter its launch.
 ► A majority of the stakeholder representatives were 
healthcare professionals, half of them being phar-
macists, which may have skewed the results.
 ► Absence of real patients with chronic illnesses and 
medications may distort results.
 ► The dynamics of the interviews may have been in-
fluenced by the fact that they were conducted as 
individual, pair or group interviews according to the 
convenience of each stakeholder.
 ► In the conceptual model building, the breakdown of 
the data to macro, meso and micro levels assisted in 
constructing a holistic understanding of the medica-
tion use process and its development needs.
AbStrACt
Objective Finland is one of the few countries that has 
established a national Medicines Information (MI) Strategy. 
The ultimate goal of the strategy is a well- implemented 
medication use process resulting in well- informed 
adherent patients. This study aimed at evaluating the 
implementation of the strategy 3 years after its launch.
Design The evaluation applied a pragmatic approach 
and was conducted by interviewing stakeholders 
involved in the National MI Network enhancing the MI 
Strategy’s implementation. The network comprises 
national key stakeholders producing and using MI. Data 
were deductively analysed according to the medication 
use process of the MI Strategy using the framework 
method, complemented with inductively derived 
categories.
Setting National implementation of the MI Strategy 
throughout the healthcare system after the first operational 
period (2012–2014) in 2015.
Participants The members of the National MI Network 
(n=79/111, participation rate 71%, representing 42/53 
stakeholder organisations).
Outcome measures A new conceptual framework 
was developed based on stakeholders’ views on well- 
implemented actions and actions needing development in 
the medication use process at (1) infrastructure (macro), 
(2) healthcare professionals (meso) and (3) patient (micro) 
levels.
results Medication counselling by community 
pharmacists was the primary implemented action, 
followed by physicians’ actions while starting a new 
medication, and advice given by nurses. The major 
development needs concerned (1) poor access to patient 
information and its transfer in healthcare, particularly 
the lack of reconciled medication lists and electronic 
health records (macro); (2) poorly functioning medication 
use process in home care and social care units, such as 
nursing homes (meso); and (3) limited patient involvement 
in their care (micro).
Conclusions Far more actions for development than 
well- established practices in the medication use process 
were identified. Major challenges found in this evaluation 
are considered in the ongoing Rational Pharmacotherapy 
Action Plan 2018–2022 by the Ministry of Social Affairs 
and Health.
IntrODuCtIOn
Carrying out long- term medication is a collab-
orative process whereby the ultimate goal is 
well- informed patients who have the capability 
and motivation to self- manage their medica-
tions. Team- based and patient- centred care 
emphasises the roles and tasks of each health-
care provider involved in the care process to 
ensure medication use in a high- quality, safe, 
effective, economical and rational manner.1 
Part of this collaborative team should be 
the patients themselves so that they can take 
responsibility for their own care and become 
empowered for self- management and self- 
care.2 Although all healthcare professionals 
involved in the medication use process should 
have clearly determined responsibilities and 
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tasks, there still exists ambiguity in this respect.3–5 Among 
healthcare professionals, there is uncertainty about their 
own roles and tasks, as well as those of other profes-
sionals.6–8 If the roles and tasks are not agreed on, it can 
lead to preventable risk situations, medication errors or 
omissions.3 9–11 It can also lead to a preventable increase 
in the medication- related burden for patients and impair 
their lived experience with the medication,12 for example, 
through inadequate support from the social and health 
service system at different phases of a long- term journey 
with a chronic illness.13 14
Easy access to reliable and timely health and medicines 
information (MI) is an integral part of the successful 
medication use process for both healthcare providers 
and medicine users.15–21 This is a strategic issue which has 
been recognised by, for instance, the European Commis-
sion.16 22 Finland is one of the few countries that has actu-
ally established a long- term strategic development plan 
for enhancing coordination between national key stake-
holders involved in producing and using MI.17 23–25 In 
Finland, MI practices have been actively developed since 
the 1980s, especially in community pharmacies (online 
supplementary appendix A).26–30 Patients have a statutory 
right to receive information about their medicines from 
their healthcare providers, with physicians and pharma-
cists being mandated to counsel on safe and appropriate 
medicine use while prescribing and dispensing.31 32 The 
current national medicines policy (2011–2020) prioritises 
the development of MI practices, particularly to improve 
coordination between MI providers and to enhance the 
use of MI sources in patient care.23 To implement these 
medicines policy actions, the Finnish Medicines Agency 
Fimea launched a national MI Strategy, ‘Rational Use 
of Medicines through Information and Guidance’, in 
2012 with the ultimate goal of a well- implemented medi-
cation use process that will result in well- informed and 
adherent patients by 2020.24 25 The special emphasis of 
the MI Strategy is on patients with long- term medications. 
Although stakeholders play a key role in the implementa-
tion of MI strategies, the implementation has not previ-
ously been evaluated from their perspective.17 The aim of 
this study was to evaluate the implementation of the MI 
Strategy in Finland from the stakeholders’ perspective.
MethODS
Key content of the MI Strategy
The national MI Strategy was established by Fimea, which 
also coordinates its implementation.24 25 The MI Strategy 
builds on the European Commission recommendations 
on MI to patients.16 The situation in other European 
Union (EU) countries was investigated by conducting 
an inventory of MI strategies in the EU countries in 
2009.33 As the UK was found to have the most advanced 
and systematic MI practices within EU, their MI Strategy, 
‘Better Information, Better Choices, Better Health’, was 
analysed in greater detail.34 35 To understand MI practices 
in Finland, an inventory of the MI research conducted in 
Finland since 2000 was carried out to identify strengths 
and development needs in MI.28 36 In addition, potential 
stakeholders to be involved in the national MI Strategy’s 
implementation were interviewed to identify their views 
on strategic core contents and proposals for actions.25
The ultimate goal of the national MI Strategy was influ-
enced by the chronic care model,37 38 which was quite 
extensively piloted in Finland in the beginning of the 
2010s (ie, at the time the MI Strategy was established) 
as a potential basis for a new social and health services 
system.39 The model puts the patient at the centre and 
encourages the creation of structures and processes that 
the support self- management of chronic diseases. The 
model is applicable to MI as there is a wealth of evidence, 
both globally and from Finland, that patients do not 
receive adequate support to self- manage their medica-
tion,21 40–43 and adherence to treatment is still an unre-
solved issue.2 44–49
Online supplementary appendix B shows the modifica-
tions of the chronic care model used in the national MI 
Strategy. A key process for patients with long- term medi-
cations is the medication use process illustrated in online 
supplementary appendix B. The medication use process 
covers activities for the needs assessment for medication, 
selection of the medication and prescribing, dispensing, 
dosing and administration, patient motivation and coun-
selling to support adherence and self- management, 
treatment follow- up and assessment of outcomes.24 The 
patient- specific medication plan is an important part of 
the medication use process, which facilitates implementa-
tion of the medication and communication on it between 
the patient and participating healthcare providers and 
organisations. This ‘patient at the centre’ model is also 
in line with the pharmaceutical care process introduced 
by the landmark article of Hepler and Strand in 1990.50
The national MI Strategy has six main goals and 37 
proposals for actions.24 Its implementation is divided into 
three operational periods (years 2012–2014, 2015–2017 
and 2018–2020). The MI Strategy aims to (1) influence the 
quality, availability and use of MI targeted to consumers 
and healthcare professionals; (2) enhance professionals’ 
MI training and competences; and (3) focus MI research 
to guide strategy work. Four working groups and their 
coordination group, that is, the National MI Network, 
form the primary resource for MI Strategy’s implementa-
tion (see table 1).24 25
Study design and setting
The medicine use process with the patient at the centre 
(online supplementary appendix B) was chosen as a 
target of the national MI Strategy’s evaluation. The study 
applied a pragmatic approach, and the evaluation was 
based on the reflections of the members of the National 
MI Network. A qualitative cross- sectional design with 
semistructured interviews among the members of the 
MI Network was used. The interviews were performed 
after the first 3- year operational period (2012–2014) of 
the national MI Strategy in 2015. During this operational 
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Table 1 Characteristics of the individual stakeholder representatives (n=79) and the stakeholder organisations (n=42) 
participating in the study (n=number of individual stakeholder representatives or stakeholder organisations)
Stakeholders by profession
Individual stakeholder 
representatives who 
participated in the study
Individual stakeholder 
representatives in the MI 
Network*
n % n %
  Pharmacists 34 43.0 41 36.9
  Physicians 17 21.5 22 19.8
  Nurses 12 15.2 15 13.5
  Others 11 13.9 21 18.9
  Practical nurses 2 2.5 2 1.8
  Healthcare students 1† 1.3 4†‡§¶ 3.6
  Dentists 0 0 1 0.9
  Not known 2 2.5 5 4.5
  Altogether 79 111
Stakeholders by type of affiliation Stakeholder organisations that 
participated in the study
Stakeholder organisations 
represented in the MI Network*
n % n %
  Healthcare centres, hospitals and hospital districts, 
hospital pharmacies and dispensaries, and university 
pharmacies
8 19.0 8 15.1
  Patient associations and organisations 8 19.0 10 18.9
  Professional organisations 7†§¶ 16.7 8†‡§¶ 15.1
  Universities 6†§¶ 14.3 6†§¶ 11.3
  Scientific societies 4†§**†† 9.5 5†§¶** 9.4
  Polytechnics and vocational institutions 3¶‡‡ 7.1 5¶‡‡ 9.4
  National authorities 2 4.8 3 5.7
  Organisations representing pharmaceutical industry 2 4.8 2 3.8
  Continuing education units 1† 2.4 1† 1.9
  Student associations 1† 2.4 4†‡§¶ 7.5
  Others 0 0 1 1.9
  Altogether 42 53
*National MI Network.
†Pharmacy.
‡Dentistry.
§Medicine.
¶Nursing.
**Clinical pharmacology.
††Psychiatry.
‡‡Pratical nursing.
MI, Medicines Information.
period, the MI Network had 111 members representing 
53 stakeholder organisations. First, an invitation to partic-
ipate in the interview was sent to all members of the MI 
Network via email. Following this, a more detailed infor-
mation letter was sent to those who agreed to participate 
in the study.
Interview guide
A semistructured interview guide with two main themes 
and eight subthemes focusing on the goals and actions of 
the national MI Strategy was developed.24 The interview 
guide was pretested in two pilot interviews with six partic-
ipants. No significant changes were made based on 
the pilot, and therefore, the data from the pilots were 
included in the study. The two main themes discussed 
in the interviews pertained to (1) reaching the goals and 
implementing the actions of the MI Strategy and (2) 
actions taken by the National MI Network. This study 
focused on the first main theme and the following ques-
tions in the interview guide: ‘If you consider the figure 
of medication use process for a patient with chronic 
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Figure 1 Content analysis process applying the framework 
method.51
diseases, then (1) what are the most crucial actions that 
have been implemented, and (2) what actions should be 
focused on in the future in order to achieve the goal of a 
well- informed, adherent patient or medicine user?’ The 
figure of the medication use process as illustrated in the 
MI Strategy was shown to the participants to stimulate 
discussion during the interview (online supplementary 
appendix B).24
Data collection
Interviews were conducted as individual, pair and group 
interviews, depending on the individual preference of 
each stakeholder in 2015. The aim was to have only one 
stakeholder organisation in each interview. Due to the 
geographical location and schedules of the participants, 
interviews were conducted face- to- face, by telephone or 
via video conferencing. One moderator (NM, a female 
pharmacist, MSc, with training in qualitative interviews) 
facilitated and audiotaped all interviews with permission 
from the participants.
Analysis
Data were analysed by applying the framework method, 
which uses both deductive and inductive content analysis 
(figure 1).51 The analysis was carried out in stages using 
Microsoft Word and Excel (Windows V.10 Home). The 
interviews were transcribed verbatim by a company special-
ising in converting to written text qualitative research 
data (stage 1). Each transcript was repeatedly read by one 
researcher (NM) while listening to the audiotapes (stage 
2). Single words, sentences or groups of sentences related 
to study questions were coded by one researcher (NM) 
and verified by another researcher (MPM) (stage 3). Any 
differences in interpretation were discussed with the 
research group and consensus was received. Once the key 
categories were identified inductively, the transcripts were 
purposively read to detect any discussion that deviated 
from these categories, and an analytical matrix was devel-
oped (stage 4). Main and subcategories were primarily 
developed deductively according to the medication use 
process previously published in the national MI Strategy 
(online supplementary appendix B)24 (stage 5). Addi-
tionally, new main and subcategories were inductively 
derived from the interview data. Codes were classified 
into main categories, and the encoded data were charted 
into a spreadsheet generated from the analytical matrix 
(stage 6). Based on the existing medication use process 
model (online supplementary appendix B) and comple-
mented by participants’views identified from the inter-
views, a new conceptual framework of the medication use 
process was developed (stage 7). The results are presented 
in accordance with two main research questions, that is, 
stakeholders’ views on (1) the well- implemented actions 
and (2) the actions needing development in the medi-
cation use process. The results are classified into three 
operational levels: infrastructure (macro), healthcare 
professional (meso) and patient (micro) levels. This follows 
the conceptual framework applied to combine the func-
tions of primary care with the dimensions of integrated 
care.52 Numbers of encodings were counted according 
to the mentions by each participant, and the summative 
numbers were set into the operational levels. The stan-
dards for reporting qualitative research was used when 
applicable.53
ensuring rigour of the analysis
In the conceptual model building, breakdown of the 
data to macro, meso and micro levels was used.52 Trust-
worthiness of the analysis process was confirmed in every 
phase, including data preparation (eg, verbatim tran-
scripts), management of data (eg, software was used in 
data coding) and reporting of results (eg, a single coder 
with a reviewer).54 55 To ensure the credibility, a previously 
known model of a medication use process24 was used as an 
analysis matrix, supplemented with the main and subcat-
egories identified inductively from the data. Addition-
ally, a theoretical method previously used in healthcare 
research52 was applied in analysing data to strengthen 
credibility. To increase the comprehensivity of the study, two 
researchers — and when necessary the whole research 
group — were involved in the data analysis process. The 
content and structure of concepts created by content 
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Figure 2 Categories of themes derived deductively (marked as blue) and inductively (marked as green) from the stakeholders’ 
interviews (n=42, involving 79 interviewees) on well- implemented actions and actions needing development in medication use 
process for patients with chronic illnesses (n=a summative of the number of the single interviewee’s mentions).
analysis were illustrated with the examples of quotations 
from various participants to indicate conformability and 
objectivity. Quotations have been selected to represent the 
identified main and subcategories in the new conceptual 
framework developed for the medication use process.
research ethics
The study was conducted according to good scientific 
practice, following the guidelines of the Finnish Advisory 
Board on Research Integrity.56 According to the guide-
lines, the study was deemed to be exempt from requiring 
approval from the research ethics committee. The 
research plan was approved by the National MI Network 
before starting the data collection. Prior to the interviews, 
participants were informed in writing about the study and 
that the interviews will be tape- recorded. At the begin-
ning of each interview, they were asked to give informed 
consent. Participation was voluntary with the opportunity 
to withdraw from the study at any time. The recordings 
and interview notes were digitally stored and encrypted 
with a password. All data were anonymised and were 
accessible only to the authors. Privacy and confidentiality 
of the individuals participating in the study were ensured 
throughout the entire research project.
Patient and public involvement
Patient participation was taken into account by inter-
viewing representatives from various national patient 
organisations who were active partners in the National 
MI Network. There was no real patients or public involve-
ment in the planning phase or design of the study. The 
results of the study will be discussed in the MI Network 
for further actions of the national MI Strategy that will be 
extended to a new term lasting until 2026.
reSultS
In total, 79 out of 111 members of the National MI 
Network participated in the study (participation rate 
71%), representing 42 out of 53 stakeholders (table 1). 
Women represented 77% (n=61) of participants. Inter-
views (n=43) were conducted as individual (n=22), pair 
(n=11) or group interviews (n=10), either face- to- face 
(79%, n=34), by telephone (12%, n=5), as video confer-
encing (7%, n=3), or as face- to- face and video confer-
encing (2%, n=1). Altogether, 3–6 participants attended 
the group interviews at a time. Four interviews included 
participants from more than one stakeholder organi-
sation. A majority of the participants were pharmacists 
(43% of all participants, n=34), physicians (22%, n=17) 
and nurses (15%, n=12). Educational units were the most 
commonly represented stakeholder group (24% of the 
stakeholder organisations, n=10), including universi-
ties, polytechnics, vocational institutions and continuing 
education units.
Well-implemented actions in the medication use process
The new conceptual framework illustrating well- 
implemented actions in the medication use process 
consisted of 10 main categories of actions (figures 2 and 
3). Of these, seven were derived deductively from the 
previous medication use process model (online supple-
mentary appendix B), and three were inductively derived 
from the data (figure 3). All the inductively derived 
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Figure 3 Stakeholders views on well- implemented actions in medication use process for patients with chronic illnesses. 
Categories derived deductively are marked as blue (n=7), and categories that emerged inductively from the stakeholders’ 
interviews are marked as green (n=3) (n=a summative of the number of the single interviewee’s mentions). aAll prescriptions 
must be electronically prescribed from 1 January 2017; bfor example, clinical pharmacology consultation services and 
comprehensive medication reviews. HCP, healthcare professional.
categories were at the infrastructure (macro) level. Around 
half of the participants (52%) reported well- implemented 
actions, mostly at the meso level (ie, healthcare profes-
sionals). Of these actions, medication counselling by 
community pharmacists was considered the best imple-
mented (n=26 mentions), followed by physicians’ perfor-
mance while starting a medication (n=14), and advice 
and guidance provided by nurses(n=14) (online supple-
mentary appendix C).
Very few mentions of the well- implemented actions at 
the infrastructure (macro) level were present (figure 3). 
These related to the patient information transfer and 
electronic health records (EHRs) (n=4 mentions of 
being well- implemented) and multiprofessional collabo-
ration (n=2), while none of the stakeholders mentioned 
management of the entire medication use process (n=0) 
or specialist services (n=0) as well- implemented.
Actions needing development in the medication use process
The stakeholders mentioned far more actions for devel-
opment than well- established practices in the medi-
cation use process (211 vs 68 mentions, respectively) 
(figures 2–4). Almost all participants (94%) raised at least 
one area for improvement (figures 2 and 4 and online 
supplementary appendix C). The highest number of 
mentions indicating a need for development concerned 
medication use process in home care and social care 
(meso) (n=34), patient information transfer and EHRs, 
including reconciled medication lists (macro)(n=33), 
and patients’ management with the medication (micro) 
(n=27). At the infrastructure (macro) level, management 
of the entire medication use process (n=24) and multi-
professional collaboration (n=23) were also frequently 
mentioned as areas for development.
In the medication use process in home care and social 
care units, such as nursing homes, most of the concerns 
related to skills, competences and inadequate training of 
practical nurses to appropriately manage the medications 
of their older clients (figure 4). A need for additional 
training in pharmacotherapy was raised, particularly for 
home care and nursing home staff to meet the require-
ments of their current work duties in geriatric care. Inad-
equate patient information transfer between care units 
and limited availability of EHRs in the medication use 
process were among the major concerns as not all profes-
sionals involved in the care team have access to complete 
and accurate patient information, such as laboratory 
results, or when the patient is transferred from a care unit 
to another. In addition, many stakeholders reported that 
the management of the entire medication use process 
needed development, indicating fragmentation, lack of 
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Figure 4 Stakeholders’ views on actions needing development in medication use process for patients with chronic illnesses. 
Categories derived deductively are marked as blue (n=7), and categories that emerged inductively from the stakeholders’ 
interviews are marked as green (n=3) (n=a summative of the number of the single interviewee's mentions. aFor example, clinical 
pharmacology consultation services and comprehensive medication reviews. HCP, healthcare professional.
coordination and poor collaboration between different 
healthcare professionals and between professionals and 
patients. They also expressed concerns on treatment 
monitoring as it was not commonly conducted very 
systematically.
Finally, poor patient involvement during the entire 
medication use process was a concern reflecting a lack 
of motivation or adherence to treatment and an inability 
or unwillingness to communicate with healthcare profes-
sionals (figure 4). A further concern was that patients do 
not always have reconciled medication lists or treatment 
plans, which may challenge not only healthcare profes-
sionals at the point of prescribing and dispensing medi-
cines but also patients while using medicines at home. 
Additionally, patients’ limited skills in searching reliable 
health and MI and insufficient medication counselling 
for particular patient groups, such as the deaf and people 
with vision impairment and using multiple medications, 
were identified as areas needing attention.
DISCuSSIOn
This study revealed that the medication use process 
of chronically ill patients using long- term medications 
requires development at every level of implementation. 
The major development needs in the infrastructure 
concern the coordination and management of care, 
transfer of patient information between care units, 
availability of a reconciled medication list, and local and 
national agreements on the responsibilities of patients 
and professionals involved in the medication use process. 
The most urgent development needs at the profes-
sional level focus on the entire medication use process 
in primary and social care, particularly in geriatric units 
where practical nurses’ competences do not meet their 
actual work responsibilities. The current medication use 
process lacks genuine patient- centeredness, manifested 
by a lack of adherence, motivation and communication, 
and the inability of patients to retrieve information. 
Patients on long- term medications need to be better 
involved in implementing their treatment by improving 
empowerment and partnership, and by finding new ways 
to support self- management and treatment commitment.
According to the stakeholders, challenges in imple-
menting the medication use process appear to be the 
greatest in primary care, especially in home care and 
social care units such as in nursing homes. This means 
social and healthcare units providing care for older adults 
in the poorest health conditions. The result may reflect 
that the Finnish population is ageing rapidly and the care 
system has not been adequately prepared for the growing 
need, for example, to train care personnel in geriatric 
pharmacotherapy to safely manage the medications. This 
is particularly the case for practical nurses whose respon-
sibility for medication management in geriatric care 
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units has increased remarkably even though their phar-
macotherapy training is limited. Practical nurses have 
3- year vocational education that focuses on supportive 
and technical nursing, and, thus, they may not have 
adequate competence to take responsibility for medica-
tion. This finding is in line with previous studies showing 
that nursing personnel (eg, practical nurses) working in 
home care and social welfare units may also lack phar-
macotherapy knowledge and skills in providing MI.28 57–60 
The same trend and challenges have been found in other 
research and development programmes in Finland and 
other countries.57 58The challenge of safe management of 
medications and polypharmacy of older adults has been 
prioritised globally in the ongoing WHO Global Patient 
Safety Programme ‘Medication Without Harm’.61 Further 
research should focus on geriatric care units in primary 
and social care to better understand the systems- based 
root causes and contributing factors of actual and poten-
tial risks in the current medication use processes.
Despite the pharmaceutical policy initiatives and wide 
recognition internationally of the importance of patient 
empowerment and involvement in healthcare,2 61 our 
study reflects that it might not be actualised in the best 
possible way. It is worth remembering that the majority of 
the interviewees in this study were health professionals, 
even in cases they represented the voice of patients. Thus, 
the results are skewed to a professional opinion even in 
the patient perspective. Nevertheless, the results send a 
clear message that patients’ involvement in their long- 
term medication should be significantly increased. To be 
successful, research and actions should focus on a patient 
approach in the implementation of long- term medica-
tions. Only the patients themselves can describe the issues 
that matter to them, affecting their motivation for treat-
ment, success of self- management and empowerment. 
Future studies should focus on real patients to explore 
their perceptions and experiences.
In this study, the stakeholders reported that patients 
are not often willing to discuss their medications and 
medication- related problems. This may reflect their 
preferences, or capacity for participation, or uncertainty 
about the responsibilities and tasks of patients’ and 
different healthcare professionals in the medication use 
process. A communicative relationship between health-
care professionals and patients is an essential driver for 
patient involvement in the medication use process, and 
for motivation for self- management and empowerment 
with medication use, especially for those with long- term 
medications.37 38 50 62–64 Healthcare professionals should 
encourage patients to share experiences and concerns 
about their treatment. They also need to ensure access to 
MI throughout the process. Although the number of MI 
sources available for patients has increased, people might 
not always receive MI from any sources.16 17 22 In Finland, 
the proportion of patients who report not receiving infor-
mation on medicines they use from any healthcare profes-
sional has more than doubled between 1999 and 2014.21 
Actions are needed to ensure equal access of MI for all 
patients and throughout the medication use process to 
support self- management and empowerment.
Infrastructural factors leading to poor access to patient 
and MI and poor adherence, such as a lack of reconciled 
medication lists and treatment plans, and lack of personal 
communication with care providers should be further 
investigated from a patient perspective.13 65 In particular, 
a reconciled medication list is essential for professionals 
and patients. For example, guidelines for patient- centred 
therapeutic counselling assume that the practitioner 
should review available patient information before the 
encounter and use the information gathered to deter-
mine what to discuss and agree on the treatment with the 
medicine user.28 30 66
Since this evaluation was conducted in 2015, short-
comings found in the infrastructure of the medication 
use process related to the coordination and availability 
of EHRs have been recognised in the ongoing Rational 
Pharmacotherapy Action Plan 2022.62 The govern-
ment programme67–69- based action plan is intended to 
strengthen the actions at the infrastructure level, which 
were minor in 2015. At the same time, it extends the 
scope of development towards the meta level, including 
health and medicines policy- making that can facilitate 
infrastructural changes in the medication use process 
through information guidance, resource allocation and 
legislation.70
Strengths and limitations of this study
This pragmatic evaluation was carried out at an early 
stage of national MI Strategy’s implementation. The aim 
was to conduct an evaluation by interview in order to 
obtain more detailed information from the stakeholders 
than would have been obtained, for example, through 
a survey. The interviews covered the whole range of 
stakeholders actively involved in implementing the MI 
Strategy. They can be assumed to be informants with the 
best understanding of the topic of research. However, the 
majority of the stakeholder representatives were health-
care professionals, half of them being pharmacists, which 
may have skewed the results. There was also an absence 
of real patients with chronic illnesses and medications, 
which may also distort results. The dynamics of the inter-
views may have been influenced by the fact that they 
were conducted as individual, pair or group interviews 
according to convenience of each stakeholder. The data 
from different types of interviews were combined, and 
the relative power of the opinions was determined by 
counting the mentions for each action. The profession 
or stakeholder group was not specified during the anal-
ysis, as the aim was to obtain an overall understanding of 
the implementation of the medication use process rather 
than to compare views between professions or stake-
holders. Moreover, participants’ demographics, except 
gender, were not collected. The figure of the medication 
use process (online supplementary appendix B) was an 
important tool in the interviews to keep the discussion 
focused on core issues. Furthermore, the figure was also 
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used as a framework in the deductive analysis, which was 
supplemented with an inductive analysis of the interview 
data. Thus, the figure was the basis for conducting the 
study, and it has a strong influence on the study findings.
Implications and future research
This has been an eye- opening study that has helped us 
to understand the functionality and shortcomings of the 
entire medication use process. The theory- based, concep-
tual model and methodology applied in this study may be 
useful for future follow- up evaluations or for evaluating 
medication use processes in other settings. The key short-
comings highlighted by the stakeholders have formed 
the core of the Rational Pharmacotherapy Action Plan 
2018–2022.62 Actions are under way to improve the coor-
dination and management of medication use process, 
for example, by launching a reconciled medication list, 
and to increase patient engagement and partnership in 
their care. The Action Plan was based on the govern-
ment programme 2015–2019, still being supported by 
the current programme as part of the ongoing social and 
health services reform.67–69 Thus, it has a strong mandate 
to change the medication use process. Such long- term 
strategies as ‘Partnership in Medicine Taking’ in the 
UK provide good practices to be benchmarked.71 The 
chronic care model is still a valid theoretical framework 
for getting the patient at the centre.37 38
Future research should focus on investigating the root 
causes for poor patient involvement in their own care. 
To improve medication adherence, the medication use 
process should be developed on a patient- oriented basis. 
This requires more qualitative research that listens to the 
long- term patients’ experiences and modifies the medi-
cation use process accordingly. The implementation of 
the medication use process should be further studied in 
different patient groups, as also suggested by the Rational 
Pharmacotherapy Action Plan.62 65 The most urgent need 
in this respect concerns older people who are at the 
highest risk of medication- related harm, particularly in 
primary care and social care institutions. Research should 
focus on enhancing coordination of care and improving 
usability of electronic systems supporting the imple-
mentation of medication use processes databases and 
systems.5 72
COnCluSIOnS
Weaknesses in the infrastructure of the medication use 
process reflecting the transfer of patient information, 
poorly functioning medication use processes in primary 
care and limited participation of patients in their care are 
priority areas while implementing the next steps of the 
national MI Strategy are found. Many of the challenges 
identified in this evaluation have been taken into consid-
eration in the MI Strategy’s implementation since 2015; 
the major challenges are also in the Rational Pharmaco-
therapy Action Plan 2018–2022 by the Ministry of Social 
Affairs and Health.
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